Dow 20,000 isn't as big of a deal as Wall Street makes it out to be.
Web-based therapy for insomnia is an effective option that could reach "previously unimaginable numbers of people," researchers suggest.
U.S. stocks gave up early gains and were little changed in light trading on Thursday as weakness in financials offset gains in healthcare companies.
Hint: You'll want to pay close attention to J&J's drug portfolio and pipeline.
By Confluence Asset Allocation Committee The rapid rise in longer duration Treasury yields since the presidential election has been surprising. As of December 8, the 10-year T-note yield was approximately 2.40%. Although President-elect Trump’s policies will probably be inflationary, it is still unclear how much of his arguably vague plans will get passed. It is…
Two companies had awful years, but both have plans for a better 2017.
Heres a visual guide for investors and potential investors in the leading diversified 3D printing company.
Gold exchange traded products, such as the SPDR Gold Shares (NYSEArca: GLD), iShares Gold Trust (NYSEArca: IAU) and ETFS Physical Swiss Gold Shares (NYSEArca: SGOL) are encountering plenty of headwinds to end 2016. However, that could be creating an opportunity for bullion-backed ETFs to rebound. Over the past month, the big-name gold ETFs have incurred…
People might have less money to spend these days, but there's a reason other than the move toward streaming to account for the decline.
Mysterious, thin, wispy clouds hide under the hazy upper atmosphere of Saturn's largest moon, Titan.